Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138000 | 1.00 | AKR1C3 (0.44) | AKR1C3APEX1CA1CA2CA4 | |
| Guanidine SCHEMBL7167005 | 0.90 | AKR1C3 (0.37) | AKR1C3APEX1CA1CA2CA4 | |
| Guanidine SCHEMBL7167001 | 0.90 | AKR1C3 (0.37) | AKR1C3APEX1CA1CA2CA4 | |
| SCHEMBL466254 | 0.83 | AKR1C3 (0.45) | AKR1C3APEX1 | |
| SCHEMBL263472 | 0.83 | AKR1C3 (0.45) | AKR1C3APEX1 | |
| SCHEMBL7130597 | 0.82 | AKR1C3 (0.47) | AKR1C3APEX1CES2CES1 | |
| SCHEMBL7130604 | 0.82 | AKR1C3 (0.47) | AKR1C3APEX1CES2CES1 | |
| SCHEMBL10668882 | 0.82 | CA1 (0.36) | CA1CA2CA4CES2CES1 | |
| SCHEMBL10668879 | 0.82 | CA1 (0.36) | CA1CA2CA4CES2CES1 | |
| SCHEMBL2570881 | 0.80 | AKR1C3 (0.53) | AKR1C3APEX1CES2CES1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664627-B1 | Surface modification method and surface-modified elastic body | SUMITOMO RUBBER IND (JP) | 2015-03-04 | — | — | EP | claimed |
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
| EP-0628610-B1 | Scratch-resistant anti-soiling and anti-graffiti coating for mouldings | ROEHM GMBH (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0628614-B1 | Acrylate based scratch-resistant coating | ROEHM GMBH (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0628610-A1 | Scratch-resistant anti-soiling and anti-graffity coating for mouldings | RÖHM GMBH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0628614-A1 | Acrylate based scratch-resistant coating | RÖHM GMBH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0160379-B1 | 2,3,5,6-TETRAFLUOROPHENYL (METH)ACRYLATES AND THEIR PRODUCTION | Nippon Shokubai Kagaku Kogyo Co., Ltd (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0160379-A1 | 2,3,5,6-tetrafluorophenyl (meth)acrylates and their production | Nippon Shokubai Kagaku Kogyo Co., Ltd (JP) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | AKR1C3 613/4885APEX1 2554/4885CA1 1481/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | AKR1C3 393/4885APEX1 971/4885CA1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.